Astronauts Leave Earth
with Perfect Vision.
They Return Going Blind.
astronauts affected
duration
NASA's next challenge
changes documented
Space blindness, formally called Spaceflight-Associated Neuro-ocular Syndrome (SANS), is a cluster of ocular changes that develop in astronauts during long-duration spaceflight. In microgravity, cerebrospinal fluid (CSF) shifts headward, raising intracranial pressure (ICP). This elevated ICP is transmitted along the optic nerve sheath, causing optic disc oedema, globe flattening, choroidal folds, cotton-wool spots, and a hyperopic refractive shift. More than 70% of long-duration ISS astronauts experience some degree of SANS. Unlike glaucoma (caused by elevated intraocular pressure), SANS is driven by elevated pressure from behind the optic nerve. There is currently no proven countermeasure. SANS is NASA's number one medical concern for a Mars mission.
The Fluid Problem:
What Gravity Actually Does to Your Body
Most people think of gravity as a force that pulls them toward the ground. The body's physiology thinks of it differently: gravity is the constant pressure gradient that organises fluid distribution from head to toe. When you stand upright, blood and cerebrospinal fluid pool relatively toward the lower body under gravitational pull — the hydrostatic pressure at the feet is higher than at the head. This gradient is so fundamental to human physiology that every organ system has evolved around it.
Remove gravity, and the gradient disappears instantly. Fluid — blood, lymph, and cerebrospinal fluid (CSF) — redistributes toward the head and upper body. Astronauts describe this immediately after launch as a "head stuffiness" — the familiar sensation of hanging upside down, but permanent. Their faces puff. Their legs thin. And the fluid pressure inside their skulls rises to levels that, sustained for months, begin to permanently remodel the structure of their eyes.
CSF FLUID DISTRIBUTION — EARTH vs MICROGRAVITY
On Earth, gravitational gradient ensures CSF pressure is higher at the feet. In microgravity, no gradient exists — CSF pools continuously toward the head, raising ICP chronically.
The optic nerve is the critical vulnerability. Unlike most cranial nerves, the optic nerve is surrounded by a sheath of dura mater that extends directly from the brain — filled with the same CSF that fills the subarachnoid space. When ICP rises, this elevated pressure is transmitted directly along the optic nerve sheath to the retrobulbar space just behind the eye. The posterior sclera, having no rigid structural support, responds by flattening. The optic disc, subjected to elevated pressure from behind, herniates slightly forward — producing the characteristic papilloedema seen in SANS.
The mechanics are not unlike what happens in idiopathic intracranial hypertension (IIH) — a condition seen predominantly in overweight young women on Earth, where CSF pressure rises without an identifiable cause. IIH produces essentially the same ocular findings as SANS: papilloedema, globe flattening, choroidal folds, and visual field loss. The crucial difference is that in IIH, the elevated ICP can be measured directly and treated. In space, the measurement itself is the challenge.
"SANS represents one of the most significant risks to crew health and performance on exploration missions. Without effective countermeasures, long-duration missions beyond low-Earth orbit — including lunar surface habitation and Mars transit — could result in permanent vision loss in crew members."
— NASA Human Research Program, Evidence Report: Risk of Spaceflight-Associated Neuro-ocular Syndrome, 2021The Timeline: How NASA
Discovered It Was Blinding Its Astronauts
SANS wasn't discovered in a lab. It was discovered retrospectively — in the post-flight medical records of astronauts who had been quietly reporting vision changes for years, without anyone connecting the dots. When NASA began systematically reviewing the ocular data in 2011, the pattern was unmistakable.
Astronauts mention "vision changes" post-flight
Individual crew members returning from long-duration Mir missions report that their vision "seems different" — slightly blurred, needing glasses they didn't need before. The reports are not systematically collected. They are attributed to normal fluid shifts and assumed to resolve.
Multiple astronauts report in-flight vision degradation
ISS crew members begin reporting that they cannot read labels or see details on laptop screens clearly — and that the problem develops gradually through the mission. Some require reading glasses that were not needed pre-launch. NASA begins collecting systematic in-flight visual acuity data.
Mader et al. paper in Ophthalmology: 7 astronauts, 7 cases of optic disc oedema
The first systematic analysis of post-ISS ocular imaging reveals optic disc oedema, globe flattening, choroidal folds, cotton-wool spots, and hyperopic shifts in multiple long-duration crew members. The paper is published in Ophthalmology and triggers immediate prioritisation. NASA designates VIIP (Visual Impairment and Intracranial Pressure) a research priority.
Twin study provides unprecedented data
Astronaut Scott Kelly completes a 340-day mission while his twin brother Mark remains on Earth. Comprehensive physiological monitoring — including ophthalmic imaging — provides the first controlled data on SANS progression. Scott develops measurable optic disc changes. The condition is renamed from VIIP to SANS. Prevalence in long-duration crew members confirmed at ~70%.
Still NASA's top-ranked medical risk for Mars
Despite 15 years of active research, no countermeasure has been confirmed effective in clinical trials. Lower body negative pressure (LBNP) devices, CSF-pressure lowering medications, dietary interventions, and exercise protocols have all been studied. SANS remains NASA Human Research Program Risk #1 for exploration missions. A Mars round-trip — 2.5 years in microgravity — could expose crew to damage far exceeding any ISS case documented to date.
Six Things That Happen
to an Astronaut's Eye in Space
Optic Disc Oedema
The optic disc swells as elevated ICP transmitted through the nerve sheath causes axoplasmic transport stasis. Grade 1–6 papilloedema measurable on OCT. Present in ~40% of long-duration crew.
Globe Flattening
The posterior sclera flattens under elevated retroorbital CSF pressure. Measurable on MRI and ultrasound. Flattening shortens the axial length and shifts the focus point — causing hyperopia.
Choroidal Folds
As the sclera flattens, the choroid (and overlying retina) buckles into visible folds visible on OCT and fluorescein angiography. Associated with distortion of vision (metamorphopsia).
Cotton-Wool Spots
Focal nerve fibre layer infarcts — identical to what is seen in early diabetic retinopathy or hypertensive retinopathy on Earth. Indicate micro-ischaemia from elevated ICP compromising optic nerve head perfusion.
Hyperopic Shift
As the globe flattens, the focal point moves forward of the retina — the eye becomes "longer-sighted" (hyperopic). Astronauts report needing reading glasses they never needed pre-flight. Can persist post-return.
Optic Nerve Sheath Dilation
The CSF-filled dura surrounding the optic nerve dilates visibly on MRI — a direct radiological sign of elevated ICP. Measurable pre- vs post-flight. Used as a proxy for ICP changes when direct lumbar puncture is not performed.
Not all astronauts develop SANS — and nobody can predict who will. Some crew members complete 6-month ISS missions with zero measurable ocular changes; others show Grade 3 papilloedema and persistent globe flattening. The variable is not mission length alone. Differences in CSF production rate, venous drainage anatomy (particularly patency of the arachnoid granulations), individual compliance of the optic nerve sheath, and possibly genetic factors in scleral stiffness all appear to modulate susceptibility. A pre-flight "SANS risk score" is one of NASA's active research goals — without it, crew selection for long-duration missions cannot be meaningfully stratified.
What Rising ICP Does
to the Optic Nerve — Simulated
SANS vs Glaucoma:
The Same Optic Nerve, Opposite Pressures
The parallel between SANS and glaucoma is one of the most intellectually fascinating intersections in contemporary ophthalmology — and it is generating new theories about optic nerve damage that may change how we approach both conditions.
| Feature | SANS (Space) | Glaucoma (Earth) |
|---|---|---|
| Primary mechanism | Elevated ICP (intracranial pressure) — posterior | Elevated IOP (intraocular pressure) — anterior |
| Force direction on optic nerve | Posterior-to-anterior compression | Anterior-to-posterior compression |
| Pressure affected | CSF pressure ↑ — aqueous IOP normal | Aqueous IOP ↑ — CSF pressure often normal |
| Optic disc appearance | Swollen / oedematous (disc raised) | Cupped / excavated (disc depressed) |
| Measurement | MRI nerve sheath, lumbar puncture (indirect) | Goldmann applanation tonometry |
| Visual field pattern | Peripheral loss (if severe); central preserved early | Arcuate scotoma; peripheral loss; central late |
| Structural OCT | RNFL thickening (oedema), then later thinning | RNFL thinning (progressive) |
| Pain | None (typically) | None (POAG); acute pain in angle closure |
| Treatment available | No confirmed countermeasure (2026) | IOP-lowering drops, laser, surgery |
| Common on Earth? | No — only in microgravity | Yes — 76M people globally |
The concept of the translaminar pressure gradient (TLPG) — the difference between IOP (pushing posteriorly through the lamina cribrosa) and ICP (pushing anteriorly through the optic nerve sheath) — is emerging as a unified framework for understanding optic nerve vulnerability. In normal eyes, IOP slightly exceeds ICP, creating a small net posterior-to-anterior force across the lamina. In glaucoma, very high IOP dramatically increases this gradient. In SANS, very high ICP reverses the gradient — the pressure from behind exceeds IOP, pushing the lamina anteriorly and causing the optic disc oedema characteristic of papilloedema.
Some researchers now believe that individuals with low ICP — a condition that has received very little clinical attention compared to high ICP — may actually be at increased risk of normal-tension glaucoma for precisely this reason: an abnormally large TLPG even at normal IOP levels. Space medicine, in other words, is teaching terrestrial ophthalmology something new about one of its oldest diseases. See our comprehensive Glaucoma guide for the full context of IOP and optic nerve damage mechanisms.
A Mars Mission Would Be
900 Days of SANS Risk
mission duration
shows SANS in 70%
in 2026
Earth–Mars (one way)
The Moon-to-Mars timeline is the forcing function. A crewed Mars mission would involve approximately 9 months of interplanetary transit each way, plus surface operations — a total of roughly 900 days in which the crew is continuously exposed to microgravity (transit phases) and reduced gravity (Mars surface, ~0.38g, likely insufficient to fully reverse the fluid redistribution observed in 0g).
The arithmetic is alarming. If the current ISS data shows that 70% of crew members develop some degree of SANS after 180 days, and if the relationship between duration and SANS severity is even partially linear, a 900-day mission represents an extraordinary visual risk. By the time a Mars crew arrives at the red planet — 9 months into the mission — they may already have Grade 3–4 papilloedema, significant visual field loss, and hyperopic shifts of 2+ dioptres.
The communication delay problem compounds this. Earth-to-Mars communication takes 3 to 22 minutes depending on orbital position. A crew member developing acute vision loss cannot be assessed in real time by an ophthalmologist on Earth. The crew physician — who may have no formal ophthalmology training — must make treatment decisions with a 14–44 minute roundtrip communication lag. There are no slit lamps on Mars. No OCT machines. No lumbar puncture facilities for ICP measurement. Whatever countermeasure exists must be deployable with the equipment that fits in the spacecraft — and must work autonomously.
Research status: Active — multiple ongoing studies including HERA chamber simulations, bed-rest analogue studies, ISS prospective cohort
Gaps identified: No validated ICP biomarker for in-mission monitoring; no confirmed pharmacological or mechanical countermeasure; SANS severity prediction model not yet validated
Artemis/Gateway relevance: Lunar Gateway operations at L2 orbit introduce lunar-distance communication latency — same autonomous management challenge as Mars
Target outcome: Operationally acceptable countermeasure with <Grade 1 SANS in 90% of crew for 1-year missions
What Is Being Tested —
None Confirmed Yet
Lower Body Negative Pressure (LBNP)
LBNP involves enclosing the lower body in a sealed chamber and applying sub-atmospheric pressure — literally creating a vacuum around the legs and abdomen that sucks fluid downward, mimicking the effect of Earth's gravity on fluid distribution. Astronauts use it daily on the ISS during exercise. In SANS research, it has shown promise in reducing ICP as measured by optic nerve sheath diameter on ultrasound — but the effect lasts only during LBNP application. Chronic daily use sufficient to prevent SANS accumulation over months is operationally demanding and has not been validated in long-duration trials.
Pharmacological ICP Reduction
Acetazolamide (Diamox) — a carbonic anhydrase inhibitor that reduces CSF production — is used to treat IIH on Earth. It is the most logical pharmacological candidate for SANS prevention. Early studies have investigated its use in bed-rest SANS analogues. Concerns include systemic side effects (electrolyte disturbances, fatigue, metabolic acidosis) that may be problematic in crew members performing high-demand operations. Topiramate (another CSF production reducer) is also under investigation.
Dietary Salt and Fluid Restriction
High dietary sodium increases fluid retention and may worsen headward fluid shift. NASA has studied low-sodium diets in spaceflight — an operationally simple intervention if confirmed effective. Results are inconclusive for SANS specifically, though sodium restriction has other cardiovascular benefits for crew health.
Artificial Gravity — The Long-Term Solution
The only intervention that would theoretically eliminate SANS entirely is artificial gravity — achieved by rotating the spacecraft to create centrifugal force equivalent to 1g. The engineering challenges are enormous (spacecraft size, rotating section design, gyroscopic effects), but artificial gravity remains the one approach that addresses the root cause rather than the downstream effects. Short-arm centrifuges — compact devices that spin astronauts horizontally for 30 minutes daily — are under active investigation as a practical approximation.
Idiopathic Intracranial Hypertension (IIH) — elevated ICP without identifiable cause in Earth-based patients — produces essentially the same ocular findings as SANS. The pathophysiology is so similar that NASA actively collaborates with IIH researchers, and IIH clinical trials of CSF pressure-lowering agents are being watched closely for SANS applicability. Both conditions produce papilloedema, globe flattening, and hyperopic shifts from the same mechanical mechanism — elevated retroorbital CSF pressure transmitted through the optic nerve sheath. Understanding SANS helps us understand IIH, and vice versa.
By the Numbers:
What the ISS Data Shows
SANS FINDINGS IN LONG-DURATION ISS CREW (Published Data — Approximate)
Sources: Mader TH et al. (2011); Lee AG et al.; Stenger MB et al.; NASA HRP Evidence Reports 2021–2024. Data represents published cohort studies; actual mission numbers may differ under NDA.
Five Things Space Blindness
Teaches Us About Eyes on Earth
-
01ICP matters as much as IOP for the optic nerveBefore SANS research, clinical ophthalmology focused almost entirely on intraocular pressure as the driver of optic nerve damage. SANS demonstrates that intracranial pressure is equally important — suggesting that normal-tension glaucoma patients with low ICP may have an underappreciated translaminar pressure gradient risk. See our Glaucoma guide.
-
02The optic nerve sheath is not just packaging — it's a pressure conduitSANS has demonstrated that the optic nerve sheath diameter on ultrasound or MRI is a reliable proxy for ICP — non-invasively, without lumbar puncture. This finding is now being used in emergency medicine to detect raised ICP in head trauma patients. Space medicine taught emergency physicians something new.
-
03Individual anatomy predicts vulnerability — and we need to measure itThe fact that some astronauts are unaffected while others develop Grade 4 SANS on identical missions proves that individual anatomy — optic nerve sheath compliance, venous drainage efficiency, scleral stiffness — determines ocular pressure tolerance. The same principle may explain why some glaucoma patients with IOP of 28 mmHg have no disc damage while others with IOP of 18 mmHg progress rapidly.
-
04Papilloedema on OCT is now recognised as an early-stage findingSANS research drove dramatic improvements in OCT-based papilloedema grading — particularly the ROTA (retinal and optic tract atrophy) scale that now allows sub-grade characterisation of optic disc oedema. These tools are now used in earth-based IIH, pseudotumour cerebri, and venous sinus thrombosis — directly benefiting millions of Earth patients from research designed for a few dozen astronauts.
-
05The retina sees everything — including pressure your brain is underFundoscopy reveals what is happening inside the skull — the retina is the only place in the body where you can directly observe brain vasculature and intracranial pressure effects without any invasive procedure. SANS made the world pay closer attention to this fact. Routine retinal imaging as a non-invasive ICP screening tool in neurological conditions is gaining research momentum as a direct result. Our Diabetic Retinopathy guide explores how much the retina reveals beyond just eye disease.
Where Agaaz Ophthalmics Fits In
SANS is a condition that currently has no established treatment — and no products can claim to prevent or reverse it. But SANS research is profoundly reshaping how ophthalmologists think about optic nerve pressure dynamics on Earth. The conditions SANS causes — papilloedema, macular changes, CSF-mediated optic nerve damage — share pathophysiology with several earth-based diseases that Agaaz's surgical portfolio serves.
Agaaz Ophthalmics supports ophthalmologists, vitreoretinal surgeons, and hospital procurement teams across India and 15+ export markets with the full surgical ophthalmic product range. The science of space is expanding what we know about eyes on Earth — and we are watching it closely.
SANS is a cluster of ocular changes that develop in astronauts during long-duration spaceflight in microgravity. The six primary findings are: optic disc oedema (swelling of the optic nerve head), globe flattening (the posterior eye wall becomes less curved), choroidal folds (the inner eye layers buckle), cotton-wool spots (focal retinal micro-infarcts), hyperopic refractive shift (distance vision improves but reading becomes harder), and optic nerve sheath dilation (visible on MRI). All of these are caused by elevated intracranial pressure from headward CSF fluid redistribution in the absence of gravity. It affects approximately 70% of long-duration ISS crew members.
Not blind — but some experience lasting vision changes. The majority of astronauts with SANS findings see partial or full recovery of optic disc oedema and some refractive change after returning to Earth's gravity. However, approximately 15% of affected crew members show structural changes — choroidal folds, globe shape alterations, or optic disc scarring — that persist permanently. These do not typically cause legal blindness, but they represent measurable, irreversible changes to the eye's structure. The concern for Mars missions is that 900 days of microgravity exposure could produce damage far exceeding current ISS case experience, potentially causing clinically significant permanent vision loss.
Duration is the key factor. Short-duration missions (Space Shuttle flights of 1–2 weeks) do cause headward fluid shift and mild ICP elevation, but the structural remodelling of the posterior sclera, optic nerve sheath, and disc that characterises SANS requires sustained elevated pressure over months. In short missions, the fluid shift reverses within hours to days of return without causing lasting structural change. SANS appears to begin manifesting clinically after approximately 4–6 weeks of continuous microgravity exposure, with findings becoming more prevalent and severe with increasing mission duration. No reliable lower threshold for SANS induction has been established.
They share the anatomical target — the optic nerve — but the mechanism is opposite. Glaucoma causes optic nerve damage by elevated intraocular pressure (IOP) from the front of the eye, compressing the optic nerve head from anterior to posterior. SANS causes optic disc changes by elevated intracranial pressure (ICP) from behind the eye, transmitted through the optic nerve sheath, pushing the disc from posterior to anterior. The net result at the optic disc is therefore different: glaucoma produces excavation (cupping), SANS produces oedema (swelling). The theoretical framework linking IOP, ICP, and the translaminar pressure gradient is one of the most active areas in optic nerve research, and SANS has significantly accelerated our understanding. Full detail in our Glaucoma guide.
This is one of the core unsolved problems in SANS research. On Earth, the gold standard for ICP measurement is lumbar puncture (spinal tap) — a procedure not feasible routinely in spaceflight. Indirect methods used in space include: optic nerve sheath diameter (ONSD) measured by ultrasound (wider sheath = higher ICP), fundoscopic photography and OCT to grade papilloedema, MRI of globe and optic nerve structure (pre- and post-flight, not in real-time), and intraocular pressure as a very indirect proxy. NASA is actively developing non-invasive continuous ICP monitoring — including near-infrared spectroscopy, tympanic membrane displacement, and other acoustic methods — but none is validated for routine spaceflight use as of 2026.
Early reports suggested SANS was more prevalent in male astronauts — which seemed paradoxical given that IIH (the earth-based equivalent) predominantly affects females. Later analysis suggests the gender disparity in early SANS data may reflect the fact that NASA's long-duration crew was predominantly male during the initial study period, rather than a true sex-based difference in susceptibility. Some researchers hypothesise that hormonal factors (oestrogen's effects on CSF dynamics and venous drainage) may be protective against SANS in women — consistent with IIH paradoxically improving during pregnancy (high oestrogen state). The question remains open and is being actively studied in more recent ISS crew data with greater gender diversity.
The optic disc findings in SANS (swelling, oedema, blurred disc margins) look very similar to papilloedema from any cause of raised ICP on Earth — including brain tumours, meningitis, and IIH. This is actually diagnostically useful: the absence of obvious earth-based causes in a returning astronaut is itself pathognomonic of SANS. The retinal findings (cotton-wool spots) resemble early diabetic retinopathy or hypertensive retinopathy. The key distinguishing feature is the constellation: globe flattening + optic disc oedema + choroidal folds together, in a person who just returned from space, is essentially diagnostic. See our Diabetic Retinopathy guide for comparison of similar retinal findings in a very different pathological context.
Not to the same degree, but head-of-bed positioning studies have shown that prolonged flat or Trendelenburg positioning (head tilted down) does cause detectable increases in ONSD and IOP in ICU patients. This is why most ICU protocols recommend head-of-bed elevation to 30–45 degrees. The key difference between hospital bed rest and spaceflight is that in a flat bed, gravity still acts vertically — there is a gravity vector, just not one aligned with the upright posture. Microgravity provides no gravity vector at all, causing dramatically greater and more persistent headward shift. Research in critical care patients has cross-pollinated with SANS research productively, particularly in developing non-invasive ICP monitoring tools.
Lower body negative pressure (LBNP) is a device that encloses the lower body from the waist down in a sealed chamber, then reduces air pressure inside the chamber below atmospheric. This creates a pressure differential that draws blood and fluid toward the lower body — mimicking the effect that Earth's gravity has on fluid distribution. On the ISS, LBNP suits are used during exercise. In SANS research, LBNP has been shown to acutely reduce optic nerve sheath diameter (a proxy for ICP) in both microgravity analogues and actual spaceflight. The limitation is that the effect is only present while the device is in use — not protective between sessions. Whether daily LBNP sessions of sufficient duration can prevent cumulative SANS over a 180-day mission has not been confirmed.
More directly than most people realise. Idiopathic Intracranial Hypertension (IIH, also called pseudotumour cerebri) produces essentially identical ocular findings to SANS — papilloedema, globe flattening, choroidal folds, hyperopic shift — from elevated CSF pressure without a tumour or other structural cause. IIH affects approximately 100,000 people in the UK alone, predominantly overweight young women. SANS research has accelerated IIH research (shared grant funding, shared imaging protocols, shared intervention trials of acetazolamide). Beyond IIH, SANS findings have contributed to understanding how CSF pressure affects the translaminar pressure gradient at the optic nerve head in glaucoma — potentially explaining why some patients develop glaucomatous damage at "normal" IOP. Space ophthalmology is generously paying down its research debt to terrestrial medicine.
// PRIMARY SOURCES //
- Mader TH, Gibson CR, Pass AF, et al. Optic disc edema, globe flattening, choroidal folds, and hyperopic shifts observed in astronauts after long-duration space flight. Ophthalmology. 2011;118(10):2058–2069. doi:10.1016/j.ophtha.2011.06.021. [The landmark paper — first systematic SANS characterisation]
- Lee AG, Mader TH, Gibson CR, et al. Spaceflight associated neuro-ocular syndrome (SANS) and the neuro-ophthalmology of space travel. J Neuroophthalmol. 2020;40(1):127–135. doi:10.1097/WNO.0000000000000913. [Comprehensive SANS review; terminology formalised]
- Stenger MB, Tarver WJ, Westby CM, et al. Evidence Report: Risk of Spaceflight-Associated Neuro-ocular Syndrome (SANS). NASA Human Research Program. 2021. [Official NASA risk classification; countermeasure gaps documented]
- Zwart SR, Gibson CR, Mader TH, et al. Vision changes after spaceflight are related to alterations in folate- and vitamin B-12-dependent one-carbon metabolism. J Nutr. 2012;142(3):427–431. [One-carbon metabolism; folate/B12 hypothesis for SANS susceptibility]
- Roberts DR, Albrecht MH, Collins HR, et al. Effects of spaceflight on astronaut brain structure as indicated on MRI. NEJM. 2017;377(18):1746–1753. doi:10.1056/NEJMoa1705129. [MRI structural brain changes; CSF shifts confirmed]
- Taibbi G, Cromwell RL, Kapoor KG, Godley BF, Vizzeri G. The effect of microgravity on ocular structures and visual function. Surv Ophthalmol. 2013;58(2):155–163. [Pre-2011 evidence review; fluid shift mechanisms]
- Lawley JS, Petersen LG, Howden EJ, et al. Effect of gravity and microgravity on intracranial pressure. J Physiol. 2017;595(6):2115–2127. doi:10.1113/JP273557. [ICP measurement in simulated microgravity; direct ICP vs ONSD correlation]
- Marshall-Goebel K, Laurie SS, Alferova IV, et al. Assessment of Jugular Venous Blood Flow Stasis and Thrombosis During Spaceflight. JAMA Netw Open. 2019;2(11):e1915011. [Venous drainage hypothesis; jugular stasis in microgravity]
- Laurie SS, Vizzeri G, Taibbi G, et al. Effects of short-term mild hypercapnia during head-down tilt on intracranial pressure and ocular structures in healthy human subjects. Physiol Rep. 2017;5(11):e13302. [Bed-rest SANS analogue; ICP surrogate methods]
- Kanas N, Manzey D. Space Psychology and Psychiatry. 3rd ed. Springer; 2017. [Chapter on medical risks including ocular complications — background context]
The eye sees everything —
including what your brain is under.
From retinal diagnostics to vitreoretinal surgery, Agaaz Ophthalmics supplies the surgical tools that manage the earth-based conditions SANS research is reshaping. Manufactured in Ahmedabad, India. Exported to 15+ countries.
Astronauts Leave Earth
with Perfect Vision.
They Return Going Blind.
astronauts affected
duration
NASA's next challenge
changes documented
Space blindness, formally called Spaceflight-Associated Neuro-ocular Syndrome (SANS), is a cluster of ocular changes that develop in astronauts during long-duration spaceflight. In microgravity, cerebrospinal fluid (CSF) shifts headward, raising intracranial pressure (ICP). This elevated ICP is transmitted along the optic nerve sheath, causing optic disc oedema, globe flattening, choroidal folds, cotton-wool spots, and a hyperopic refractive shift. More than 70% of long-duration ISS astronauts experience some degree of SANS. Unlike glaucoma (caused by elevated intraocular pressure), SANS is driven by elevated pressure from behind the optic nerve. There is currently no proven countermeasure. SANS is NASA's number one medical concern for a Mars mission.
The Fluid Problem:
What Gravity Actually Does to Your Body
Most people think of gravity as a force that pulls them toward the ground. The body's physiology thinks of it differently: gravity is the constant pressure gradient that organises fluid distribution from head to toe. When you stand upright, blood and cerebrospinal fluid pool relatively toward the lower body under gravitational pull — the hydrostatic pressure at the feet is higher than at the head. This gradient is so fundamental to human physiology that every organ system has evolved around it.
Remove gravity, and the gradient disappears instantly. Fluid — blood, lymph, and cerebrospinal fluid (CSF) — redistributes toward the head and upper body. Astronauts describe this immediately after launch as a "head stuffiness" — the familiar sensation of hanging upside down, but permanent. Their faces puff. Their legs thin. And the fluid pressure inside their skulls rises to levels that, sustained for months, begin to permanently remodel the structure of their eyes.
CSF FLUID DISTRIBUTION — EARTH vs MICROGRAVITY
On Earth, gravitational gradient ensures CSF pressure is higher at the feet. In microgravity, no gradient exists — CSF pools continuously toward the head, raising ICP chronically.
The optic nerve is the critical vulnerability. Unlike most cranial nerves, the optic nerve is surrounded by a sheath of dura mater that extends directly from the brain — filled with the same CSF that fills the subarachnoid space. When ICP rises, this elevated pressure is transmitted directly along the optic nerve sheath to the retrobulbar space just behind the eye. The posterior sclera, having no rigid structural support, responds by flattening. The optic disc, subjected to elevated pressure from behind, herniates slightly forward — producing the characteristic papilloedema seen in SANS.
The mechanics are not unlike what happens in idiopathic intracranial hypertension (IIH) — a condition seen predominantly in overweight young women on Earth, where CSF pressure rises without an identifiable cause. IIH produces essentially the same ocular findings as SANS: papilloedema, globe flattening, choroidal folds, and visual field loss. The crucial difference is that in IIH, the elevated ICP can be measured directly and treated. In space, the measurement itself is the challenge.
"SANS represents one of the most significant risks to crew health and performance on exploration missions. Without effective countermeasures, long-duration missions beyond low-Earth orbit — including lunar surface habitation and Mars transit — could result in permanent vision loss in crew members."
— NASA Human Research Program, Evidence Report: Risk of Spaceflight-Associated Neuro-ocular Syndrome, 2021The Timeline: How NASA
Discovered It Was Blinding Its Astronauts
SANS wasn't discovered in a lab. It was discovered retrospectively — in the post-flight medical records of astronauts who had been quietly reporting vision changes for years, without anyone connecting the dots. When NASA began systematically reviewing the ocular data in 2011, the pattern was unmistakable.
Astronauts mention "vision changes" post-flight
Individual crew members returning from long-duration Mir missions report that their vision "seems different" — slightly blurred, needing glasses they didn't need before. The reports are not systematically collected. They are attributed to normal fluid shifts and assumed to resolve.
Multiple astronauts report in-flight vision degradation
ISS crew members begin reporting that they cannot read labels or see details on laptop screens clearly — and that the problem develops gradually through the mission. Some require reading glasses that were not needed pre-launch. NASA begins collecting systematic in-flight visual acuity data.
Mader et al. paper in Ophthalmology: 7 astronauts, 7 cases of optic disc oedema
The first systematic analysis of post-ISS ocular imaging reveals optic disc oedema, globe flattening, choroidal folds, cotton-wool spots, and hyperopic shifts in multiple long-duration crew members. The paper is published in Ophthalmology and triggers immediate prioritisation. NASA designates VIIP (Visual Impairment and Intracranial Pressure) a research priority.
Twin study provides unprecedented data
Astronaut Scott Kelly completes a 340-day mission while his twin brother Mark remains on Earth. Comprehensive physiological monitoring — including ophthalmic imaging — provides the first controlled data on SANS progression. Scott develops measurable optic disc changes. The condition is renamed from VIIP to SANS. Prevalence in long-duration crew members confirmed at ~70%.
Still NASA's top-ranked medical risk for Mars
Despite 15 years of active research, no countermeasure has been confirmed effective in clinical trials. Lower body negative pressure (LBNP) devices, CSF-pressure lowering medications, dietary interventions, and exercise protocols have all been studied. SANS remains NASA Human Research Program Risk #1 for exploration missions. A Mars round-trip — 2.5 years in microgravity — could expose crew to damage far exceeding any ISS case documented to date.
Six Things That Happen
to an Astronaut's Eye in Space
Optic Disc Oedema
The optic disc swells as elevated ICP transmitted through the nerve sheath causes axoplasmic transport stasis. Grade 1–6 papilloedema measurable on OCT. Present in ~40% of long-duration crew.
Globe Flattening
The posterior sclera flattens under elevated retroorbital CSF pressure. Measurable on MRI and ultrasound. Flattening shortens the axial length and shifts the focus point — causing hyperopia.
Choroidal Folds
As the sclera flattens, the choroid (and overlying retina) buckles into visible folds visible on OCT and fluorescein angiography. Associated with distortion of vision (metamorphopsia).
Cotton-Wool Spots
Focal nerve fibre layer infarcts — identical to what is seen in early diabetic retinopathy or hypertensive retinopathy on Earth. Indicate micro-ischaemia from elevated ICP compromising optic nerve head perfusion.
Hyperopic Shift
As the globe flattens, the focal point moves forward of the retina — the eye becomes "longer-sighted" (hyperopic). Astronauts report needing reading glasses they never needed pre-flight. Can persist post-return.
Optic Nerve Sheath Dilation
The CSF-filled dura surrounding the optic nerve dilates visibly on MRI — a direct radiological sign of elevated ICP. Measurable pre- vs post-flight. Used as a proxy for ICP changes when direct lumbar puncture is not performed.
Not all astronauts develop SANS — and nobody can predict who will. Some crew members complete 6-month ISS missions with zero measurable ocular changes; others show Grade 3 papilloedema and persistent globe flattening. The variable is not mission length alone. Differences in CSF production rate, venous drainage anatomy (particularly patency of the arachnoid granulations), individual compliance of the optic nerve sheath, and possibly genetic factors in scleral stiffness all appear to modulate susceptibility. A pre-flight "SANS risk score" is one of NASA's active research goals — without it, crew selection for long-duration missions cannot be meaningfully stratified.
What Rising ICP Does
to the Optic Nerve — Simulated
SANS vs Glaucoma:
The Same Optic Nerve, Opposite Pressures
The parallel between SANS and glaucoma is one of the most intellectually fascinating intersections in contemporary ophthalmology — and it is generating new theories about optic nerve damage that may change how we approach both conditions.
| Feature | SANS (Space) | Glaucoma (Earth) |
|---|---|---|
| Primary mechanism | Elevated ICP (intracranial pressure) — posterior | Elevated IOP (intraocular pressure) — anterior |
| Force direction on optic nerve | Posterior-to-anterior compression | Anterior-to-posterior compression |
| Pressure affected | CSF pressure ↑ — aqueous IOP normal | Aqueous IOP ↑ — CSF pressure often normal |
| Optic disc appearance | Swollen / oedematous (disc raised) | Cupped / excavated (disc depressed) |
| Measurement | MRI nerve sheath, lumbar puncture (indirect) | Goldmann applanation tonometry |
| Visual field pattern | Peripheral loss (if severe); central preserved early | Arcuate scotoma; peripheral loss; central late |
| Structural OCT | RNFL thickening (oedema), then later thinning | RNFL thinning (progressive) |
| Pain | None (typically) | None (POAG); acute pain in angle closure |
| Treatment available | No confirmed countermeasure (2026) | IOP-lowering drops, laser, surgery |
| Common on Earth? | No — only in microgravity | Yes — 76M people globally |
The concept of the translaminar pressure gradient (TLPG) — the difference between IOP (pushing posteriorly through the lamina cribrosa) and ICP (pushing anteriorly through the optic nerve sheath) — is emerging as a unified framework for understanding optic nerve vulnerability. In normal eyes, IOP slightly exceeds ICP, creating a small net posterior-to-anterior force across the lamina. In glaucoma, very high IOP dramatically increases this gradient. In SANS, very high ICP reverses the gradient — the pressure from behind exceeds IOP, pushing the lamina anteriorly and causing the optic disc oedema characteristic of papilloedema.
Some researchers now believe that individuals with low ICP — a condition that has received very little clinical attention compared to high ICP — may actually be at increased risk of normal-tension glaucoma for precisely this reason: an abnormally large TLPG even at normal IOP levels. Space medicine, in other words, is teaching terrestrial ophthalmology something new about one of its oldest diseases. See our comprehensive Glaucoma guide for the full context of IOP and optic nerve damage mechanisms.
A Mars Mission Would Be
900 Days of SANS Risk
mission duration
shows SANS in 70%
in 2026
Earth–Mars (one way)
The Moon-to-Mars timeline is the forcing function. A crewed Mars mission would involve approximately 9 months of interplanetary transit each way, plus surface operations — a total of roughly 900 days in which the crew is continuously exposed to microgravity (transit phases) and reduced gravity (Mars surface, ~0.38g, likely insufficient to fully reverse the fluid redistribution observed in 0g).
The arithmetic is alarming. If the current ISS data shows that 70% of crew members develop some degree of SANS after 180 days, and if the relationship between duration and SANS severity is even partially linear, a 900-day mission represents an extraordinary visual risk. By the time a Mars crew arrives at the red planet — 9 months into the mission — they may already have Grade 3–4 papilloedema, significant visual field loss, and hyperopic shifts of 2+ dioptres.
The communication delay problem compounds this. Earth-to-Mars communication takes 3 to 22 minutes depending on orbital position. A crew member developing acute vision loss cannot be assessed in real time by an ophthalmologist on Earth. The crew physician — who may have no formal ophthalmology training — must make treatment decisions with a 14–44 minute roundtrip communication lag. There are no slit lamps on Mars. No OCT machines. No lumbar puncture facilities for ICP measurement. Whatever countermeasure exists must be deployable with the equipment that fits in the spacecraft — and must work autonomously.
Research status: Active — multiple ongoing studies including HERA chamber simulations, bed-rest analogue studies, ISS prospective cohort
Gaps identified: No validated ICP biomarker for in-mission monitoring; no confirmed pharmacological or mechanical countermeasure; SANS severity prediction model not yet validated
Artemis/Gateway relevance: Lunar Gateway operations at L2 orbit introduce lunar-distance communication latency — same autonomous management challenge as Mars
Target outcome: Operationally acceptable countermeasure with <Grade 1 SANS in 90% of crew for 1-year missions
What Is Being Tested —
None Confirmed Yet
Lower Body Negative Pressure (LBNP)
LBNP involves enclosing the lower body in a sealed chamber and applying sub-atmospheric pressure — literally creating a vacuum around the legs and abdomen that sucks fluid downward, mimicking the effect of Earth's gravity on fluid distribution. Astronauts use it daily on the ISS during exercise. In SANS research, it has shown promise in reducing ICP as measured by optic nerve sheath diameter on ultrasound — but the effect lasts only during LBNP application. Chronic daily use sufficient to prevent SANS accumulation over months is operationally demanding and has not been validated in long-duration trials.
Pharmacological ICP Reduction
Acetazolamide (Diamox) — a carbonic anhydrase inhibitor that reduces CSF production — is used to treat IIH on Earth. It is the most logical pharmacological candidate for SANS prevention. Early studies have investigated its use in bed-rest SANS analogues. Concerns include systemic side effects (electrolyte disturbances, fatigue, metabolic acidosis) that may be problematic in crew members performing high-demand operations. Topiramate (another CSF production reducer) is also under investigation.
Dietary Salt and Fluid Restriction
High dietary sodium increases fluid retention and may worsen headward fluid shift. NASA has studied low-sodium diets in spaceflight — an operationally simple intervention if confirmed effective. Results are inconclusive for SANS specifically, though sodium restriction has other cardiovascular benefits for crew health.
Artificial Gravity — The Long-Term Solution
The only intervention that would theoretically eliminate SANS entirely is artificial gravity — achieved by rotating the spacecraft to create centrifugal force equivalent to 1g. The engineering challenges are enormous (spacecraft size, rotating section design, gyroscopic effects), but artificial gravity remains the one approach that addresses the root cause rather than the downstream effects. Short-arm centrifuges — compact devices that spin astronauts horizontally for 30 minutes daily — are under active investigation as a practical approximation.
Idiopathic Intracranial Hypertension (IIH) — elevated ICP without identifiable cause in Earth-based patients — produces essentially the same ocular findings as SANS. The pathophysiology is so similar that NASA actively collaborates with IIH researchers, and IIH clinical trials of CSF pressure-lowering agents are being watched closely for SANS applicability. Both conditions produce papilloedema, globe flattening, and hyperopic shifts from the same mechanical mechanism — elevated retroorbital CSF pressure transmitted through the optic nerve sheath. Understanding SANS helps us understand IIH, and vice versa.
By the Numbers:
What the ISS Data Shows
SANS FINDINGS IN LONG-DURATION ISS CREW (Published Data — Approximate)
Sources: Mader TH et al. (2011); Lee AG et al.; Stenger MB et al.; NASA HRP Evidence Reports 2021–2024. Data represents published cohort studies; actual mission numbers may differ under NDA.
Five Things Space Blindness
Teaches Us About Eyes on Earth
-
01ICP matters as much as IOP for the optic nerveBefore SANS research, clinical ophthalmology focused almost entirely on intraocular pressure as the driver of optic nerve damage. SANS demonstrates that intracranial pressure is equally important — suggesting that normal-tension glaucoma patients with low ICP may have an underappreciated translaminar pressure gradient risk. See our Glaucoma guide.
-
02The optic nerve sheath is not just packaging — it's a pressure conduitSANS has demonstrated that the optic nerve sheath diameter on ultrasound or MRI is a reliable proxy for ICP — non-invasively, without lumbar puncture. This finding is now being used in emergency medicine to detect raised ICP in head trauma patients. Space medicine taught emergency physicians something new.
-
03Individual anatomy predicts vulnerability — and we need to measure itThe fact that some astronauts are unaffected while others develop Grade 4 SANS on identical missions proves that individual anatomy — optic nerve sheath compliance, venous drainage efficiency, scleral stiffness — determines ocular pressure tolerance. The same principle may explain why some glaucoma patients with IOP of 28 mmHg have no disc damage while others with IOP of 18 mmHg progress rapidly.
-
04Papilloedema on OCT is now recognised as an early-stage findingSANS research drove dramatic improvements in OCT-based papilloedema grading — particularly the ROTA (retinal and optic tract atrophy) scale that now allows sub-grade characterisation of optic disc oedema. These tools are now used in earth-based IIH, pseudotumour cerebri, and venous sinus thrombosis — directly benefiting millions of Earth patients from research designed for a few dozen astronauts.
-
05The retina sees everything — including pressure your brain is underFundoscopy reveals what is happening inside the skull — the retina is the only place in the body where you can directly observe brain vasculature and intracranial pressure effects without any invasive procedure. SANS made the world pay closer attention to this fact. Routine retinal imaging as a non-invasive ICP screening tool in neurological conditions is gaining research momentum as a direct result. Our Diabetic Retinopathy guide explores how much the retina reveals beyond just eye disease.
Where Agaaz Ophthalmics Fits In
SANS is a condition that currently has no established treatment — and no products can claim to prevent or reverse it. But SANS research is profoundly reshaping how ophthalmologists think about optic nerve pressure dynamics on Earth. The conditions SANS causes — papilloedema, macular changes, CSF-mediated optic nerve damage — share pathophysiology with several earth-based diseases that Agaaz's surgical portfolio serves.
Agaaz Ophthalmics supports ophthalmologists, vitreoretinal surgeons, and hospital procurement teams across India and 15+ export markets with the full surgical ophthalmic product range. The science of space is expanding what we know about eyes on Earth — and we are watching it closely.
SANS is a cluster of ocular changes that develop in astronauts during long-duration spaceflight in microgravity. The six primary findings are: optic disc oedema (swelling of the optic nerve head), globe flattening (the posterior eye wall becomes less curved), choroidal folds (the inner eye layers buckle), cotton-wool spots (focal retinal micro-infarcts), hyperopic refractive shift (distance vision improves but reading becomes harder), and optic nerve sheath dilation (visible on MRI). All of these are caused by elevated intracranial pressure from headward CSF fluid redistribution in the absence of gravity. It affects approximately 70% of long-duration ISS crew members.
Not blind — but some experience lasting vision changes. The majority of astronauts with SANS findings see partial or full recovery of optic disc oedema and some refractive change after returning to Earth's gravity. However, approximately 15% of affected crew members show structural changes — choroidal folds, globe shape alterations, or optic disc scarring — that persist permanently. These do not typically cause legal blindness, but they represent measurable, irreversible changes to the eye's structure. The concern for Mars missions is that 900 days of microgravity exposure could produce damage far exceeding current ISS case experience, potentially causing clinically significant permanent vision loss.
Duration is the key factor. Short-duration missions (Space Shuttle flights of 1–2 weeks) do cause headward fluid shift and mild ICP elevation, but the structural remodelling of the posterior sclera, optic nerve sheath, and disc that characterises SANS requires sustained elevated pressure over months. In short missions, the fluid shift reverses within hours to days of return without causing lasting structural change. SANS appears to begin manifesting clinically after approximately 4–6 weeks of continuous microgravity exposure, with findings becoming more prevalent and severe with increasing mission duration. No reliable lower threshold for SANS induction has been established.
They share the anatomical target — the optic nerve — but the mechanism is opposite. Glaucoma causes optic nerve damage by elevated intraocular pressure (IOP) from the front of the eye, compressing the optic nerve head from anterior to posterior. SANS causes optic disc changes by elevated intracranial pressure (ICP) from behind the eye, transmitted through the optic nerve sheath, pushing the disc from posterior to anterior. The net result at the optic disc is therefore different: glaucoma produces excavation (cupping), SANS produces oedema (swelling). The theoretical framework linking IOP, ICP, and the translaminar pressure gradient is one of the most active areas in optic nerve research, and SANS has significantly accelerated our understanding. Full detail in our Glaucoma guide.
This is one of the core unsolved problems in SANS research. On Earth, the gold standard for ICP measurement is lumbar puncture (spinal tap) — a procedure not feasible routinely in spaceflight. Indirect methods used in space include: optic nerve sheath diameter (ONSD) measured by ultrasound (wider sheath = higher ICP), fundoscopic photography and OCT to grade papilloedema, MRI of globe and optic nerve structure (pre- and post-flight, not in real-time), and intraocular pressure as a very indirect proxy. NASA is actively developing non-invasive continuous ICP monitoring — including near-infrared spectroscopy, tympanic membrane displacement, and other acoustic methods — but none is validated for routine spaceflight use as of 2026.
Early reports suggested SANS was more prevalent in male astronauts — which seemed paradoxical given that IIH (the earth-based equivalent) predominantly affects females. Later analysis suggests the gender disparity in early SANS data may reflect the fact that NASA's long-duration crew was predominantly male during the initial study period, rather than a true sex-based difference in susceptibility. Some researchers hypothesise that hormonal factors (oestrogen's effects on CSF dynamics and venous drainage) may be protective against SANS in women — consistent with IIH paradoxically improving during pregnancy (high oestrogen state). The question remains open and is being actively studied in more recent ISS crew data with greater gender diversity.
The optic disc findings in SANS (swelling, oedema, blurred disc margins) look very similar to papilloedema from any cause of raised ICP on Earth — including brain tumours, meningitis, and IIH. This is actually diagnostically useful: the absence of obvious earth-based causes in a returning astronaut is itself pathognomonic of SANS. The retinal findings (cotton-wool spots) resemble early diabetic retinopathy or hypertensive retinopathy. The key distinguishing feature is the constellation: globe flattening + optic disc oedema + choroidal folds together, in a person who just returned from space, is essentially diagnostic. See our Diabetic Retinopathy guide for comparison of similar retinal findings in a very different pathological context.
Not to the same degree, but head-of-bed positioning studies have shown that prolonged flat or Trendelenburg positioning (head tilted down) does cause detectable increases in ONSD and IOP in ICU patients. This is why most ICU protocols recommend head-of-bed elevation to 30–45 degrees. The key difference between hospital bed rest and spaceflight is that in a flat bed, gravity still acts vertically — there is a gravity vector, just not one aligned with the upright posture. Microgravity provides no gravity vector at all, causing dramatically greater and more persistent headward shift. Research in critical care patients has cross-pollinated with SANS research productively, particularly in developing non-invasive ICP monitoring tools.
Lower body negative pressure (LBNP) is a device that encloses the lower body from the waist down in a sealed chamber, then reduces air pressure inside the chamber below atmospheric. This creates a pressure differential that draws blood and fluid toward the lower body — mimicking the effect that Earth's gravity has on fluid distribution. On the ISS, LBNP suits are used during exercise. In SANS research, LBNP has been shown to acutely reduce optic nerve sheath diameter (a proxy for ICP) in both microgravity analogues and actual spaceflight. The limitation is that the effect is only present while the device is in use — not protective between sessions. Whether daily LBNP sessions of sufficient duration can prevent cumulative SANS over a 180-day mission has not been confirmed.
More directly than most people realise. Idiopathic Intracranial Hypertension (IIH, also called pseudotumour cerebri) produces essentially identical ocular findings to SANS — papilloedema, globe flattening, choroidal folds, hyperopic shift — from elevated CSF pressure without a tumour or other structural cause. IIH affects approximately 100,000 people in the UK alone, predominantly overweight young women. SANS research has accelerated IIH research (shared grant funding, shared imaging protocols, shared intervention trials of acetazolamide). Beyond IIH, SANS findings have contributed to understanding how CSF pressure affects the translaminar pressure gradient at the optic nerve head in glaucoma — potentially explaining why some patients develop glaucomatous damage at "normal" IOP. Space ophthalmology is generously paying down its research debt to terrestrial medicine.
// PRIMARY SOURCES //
- Mader TH, Gibson CR, Pass AF, et al. Optic disc edema, globe flattening, choroidal folds, and hyperopic shifts observed in astronauts after long-duration space flight. Ophthalmology. 2011;118(10):2058–2069. doi:10.1016/j.ophtha.2011.06.021. [The landmark paper — first systematic SANS characterisation]
- Lee AG, Mader TH, Gibson CR, et al. Spaceflight associated neuro-ocular syndrome (SANS) and the neuro-ophthalmology of space travel. J Neuroophthalmol. 2020;40(1):127–135. doi:10.1097/WNO.0000000000000913. [Comprehensive SANS review; terminology formalised]
- Stenger MB, Tarver WJ, Westby CM, et al. Evidence Report: Risk of Spaceflight-Associated Neuro-ocular Syndrome (SANS). NASA Human Research Program. 2021. [Official NASA risk classification; countermeasure gaps documented]
- Zwart SR, Gibson CR, Mader TH, et al. Vision changes after spaceflight are related to alterations in folate- and vitamin B-12-dependent one-carbon metabolism. J Nutr. 2012;142(3):427–431. [One-carbon metabolism; folate/B12 hypothesis for SANS susceptibility]
- Roberts DR, Albrecht MH, Collins HR, et al. Effects of spaceflight on astronaut brain structure as indicated on MRI. NEJM. 2017;377(18):1746–1753. doi:10.1056/NEJMoa1705129. [MRI structural brain changes; CSF shifts confirmed]
- Taibbi G, Cromwell RL, Kapoor KG, Godley BF, Vizzeri G. The effect of microgravity on ocular structures and visual function. Surv Ophthalmol. 2013;58(2):155–163. [Pre-2011 evidence review; fluid shift mechanisms]
- Lawley JS, Petersen LG, Howden EJ, et al. Effect of gravity and microgravity on intracranial pressure. J Physiol. 2017;595(6):2115–2127. doi:10.1113/JP273557. [ICP measurement in simulated microgravity; direct ICP vs ONSD correlation]
- Marshall-Goebel K, Laurie SS, Alferova IV, et al. Assessment of Jugular Venous Blood Flow Stasis and Thrombosis During Spaceflight. JAMA Netw Open. 2019;2(11):e1915011. [Venous drainage hypothesis; jugular stasis in microgravity]
- Laurie SS, Vizzeri G, Taibbi G, et al. Effects of short-term mild hypercapnia during head-down tilt on intracranial pressure and ocular structures in healthy human subjects. Physiol Rep. 2017;5(11):e13302. [Bed-rest SANS analogue; ICP surrogate methods]
- Kanas N, Manzey D. Space Psychology and Psychiatry. 3rd ed. Springer; 2017. [Chapter on medical risks including ocular complications — background context]
The eye sees everything —
including what your brain is under.
From retinal diagnostics to vitreoretinal surgery, Agaaz Ophthalmics supplies the surgical tools that manage the earth-based conditions SANS research is reshaping. Manufactured in Ahmedabad, India. Exported to 15+ countries.
Start writing here...
Space Blindness: Why Astronauts Return Going Blind 2026